Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Kidney Disease (CKD) Hemodialysis Clear all
Completed No phase listed Observational

Endothelial Function and Arterio-Venous Fistula Maturation

NCT01604473
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 90 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

NCT02837237
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 8, 2026, 1:14 AM EDT
Terminated Phase 4 Interventional

Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

NCT00062699
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Zemplar (paricalcitol injection), Calcijex
Drug
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
60
States / cities
Tuscaloosa, Alabama • Inglewood, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

NCT03400033
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

NCT02581124
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Lapatinib
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients

NCT00679991
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
PRT-201
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Portland, Maine + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Phosphate Levels in Patients With Chronic Kidney Disease

NCT00824460
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
1.25 g PA21 (250 mg iron), 5.0 g PA21 (1,000 mg iron), 7.5 g PA21 (1,500 mg iron), 10.0 g PA21 (2,000 mg iron), 12.5 g PA21 (2,500 mg iron), Sevelamer hydrochloride
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Arvada, Colorado • Denver, Colorado • Pembroke Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Comparison of Standard Versus Low Bicarbonate Hemodialysis

NCT01777178
View directory record Official record
Conditions
Chronic Kidney Disease, Metabolic Acidosis
Interventions
Low bicarbonate dialysis
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Not applicable Interventional

Dietary Protein Requirements in Hemodialysis Patients

NCT02194114
View directory record Official record
Conditions
Chronic Renal Failure, End-Stage Renal Disease
Interventions
Protein Diet
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 3 Interventional

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

NCT00561093
View directory record Official record
Conditions
Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions
pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
Drug · Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Irvine, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 8, 2026, 1:14 AM EDT
Terminated Not applicable Interventional Results available

Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters

NCT02796300
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Bioflo Dialysis Catheter, Palindrome Dialysis Catheter
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 8, 2026, 1:14 AM EDT
Recruiting Not applicable Interventional

Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets)

NCT05465044
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) Stage 5, Kidney Dysfunction Requiring Dialysis (KDRD), Dialysis Dependency
Interventions
Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule, Thrice-Weekly Hemodialysis
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Long Beach, California • West Los Angeles, California • West Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 4 Interventional Results available

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

NCT01950819
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Interventions
Induction therapy, Corticosteroids, EVR+rCNI, MPA+sCNI
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
40
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

NCT03799627
View directory record Official record
Conditions
Anemia, Dialysis-dependent Chronic Kidney Disease
Interventions
Vadadustat, Epoetin Alfa, Vadadustat TIW
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Fresno, California • Granada Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

NCT02513303
View directory record Official record
Conditions
Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD, Chronic Kidney Failure, Complication of Hemodialysis, Vascular Access Complication, Arteriovenous Fistula
Interventions
Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI)
Drug · Procedure · Device
Lead sponsor
Vascular Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Huntsville, Alabama • Phoenix, Arizona • Escondido, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 8, 2026, 1:14 AM EDT
Recruiting Not applicable Interventional

Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients

NCT06978127
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Hemodialysis
Interventions
Technology Assisted Stepped Collaborative Care, Usual Care Arm
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Albuquerque, New Mexico • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Not applicable Interventional

Effect of Exercise on Endothelial Function and Vascular Compliance in Chronic Kidney Disease

NCT01068314
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Repetitive arm exercise
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

NCT01503021
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
SFP, Placebo
Drug · Other
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
28
States / cities
Mobile, Alabama • Northridge, California • Arvada, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 8, 2026, 1:14 AM EDT
Enrolling by invitation No phase listed Observational

Improving Continuous Renal Replacement Therapy Outcomes in Neonates and Infants Through Interdisciplinary Collaboration

NCT05161078
View directory record Official record
Conditions
Acute Kidney Injury, Chronic Kidney Diseases, Renal Dialysis
Interventions
CARPEDIEM
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Mitochondria and Chronic Kidney Disease

NCT03177798
View directory record Official record
Conditions
Hemodialysis-Induced Symptom, Mitochondrial Diseases
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 78 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

NCT03029247
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Epoetin alfa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
La Mesa, California • Lakewood, Colorado • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 8, 2026, 1:14 AM EDT
Completed Phase 2 Interventional

Behavioral Intervention and Adherence in Dialysis

NCT01066949
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Behavioral self mangement, Support and discussion
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Dubuque, Iowa • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 8, 2026, 1:14 AM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

NCT04671771
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Kidney Failure, Chronic Renal Disease, Hemodialysis
Interventions
InnAVasc Arteriovenous Graft (IG) surgical implant
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 90 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Sarasota, Florida • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 8, 2026, 1:14 AM EDT